Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.23 (
MMP
)
4,246
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Studies suggest the expression of cyclooxygenase-2 (COX-2) and
matrilysin
(MMP-7) increase in the early stages of colorectal carcinogenesis, however their interaction with other molecular markers is poorly understood. Results from cell line studies and mouse models suggest polyomavirus enhancer activator 3 (PEA3) may play a role in the activation of COX-2 and MMP-7 promoters. However, the role of
E1A-F
, the human homolog of murine PEA3, in colorectal cancer (CRC) development has not been elucidated. In this study, we used real-time reverse transcription (RT)-polymerase chain reaction (PCR) to measure the levels of
E1A-F
, COX-2, and MMP-7 in matched normal mucosa, adenomas, and/or carcinomas from 128 patients. Our results demonstrate significant overexpression of
E1A-F
and MMP-7 in adenomas and
E1A-F
, COX-2, and MMP-7 in carcinomas. In carcinomas,
E1A-F
expression was significantly associated with both COX-2 and MMP-7 overexpression. These results suggest
E1A-F
is overexpressed in early stages of human CRC development and may be an important factor in the overexpression of COX-2 and MMP-7.
...
PMID:E1A-F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase-2 and matrix metalloproteinase-7. 1580 Sep 27